Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Strong demand for Glaxo's Trelegy Ellipta is likely to have driven royalties for Innoviva (INVA) in the fourth quarter.

What's in Store for Innoviva (INVA) This Earnings Season?

In the latest trading session, Innoviva (INVA) closed at $12.51, marking a +1.71% move from the previous day.

Innoviva (INVA) Gains As Market Dips: What You Should Know

Customers Bancorp

Plains GP Hlds

Smith & Wesson Brands

Top Ranked Value Stocks to Buy for January 5th

Danaos

Michaels

Office Depot

Top Ranked Value Stocks to Buy for January 4th

Top Ranked Value Stocks to Buy for December 29th

A-Mark Precious Metals

Top Ranked Value Stocks to Buy for December 28th

Clearwater Paper

Top Ranked Value Stocks to Buy for December 24th

We believe that Innoviva stock, a pharmaceuticals royalty management company, is a good buying opportunity at the present time. INVA stock trades near $12 currently and it is, in fact, down 17% from its pre-Covid high of $15 in February 2020 – just before the coronavirus pandemic hit the world.

Innoviva Can Offer 25% Upside From Current Levels

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Innoviva (INVA) a Great Value Stock Right Now?

BioDelivery Sciences

BioMarin Pharmaceutical

Catalyst Pharmaceuticals

Novavax

Vertex Pharmaceuticals

Vaxart

Voyager Therapeutics

These are the biotech stocks with the best value, fastest growth, and most momentum for Q1 2021.

Top Biotech Stocks for Q1 2021

Capital Product Partners

360 Finance Inc - ADR

Top Ranked Value Stocks to Buy for December 7th

California Water Service Group

Owens & Minor

Standard Motor Products

To combat market volatility, it is of utmost importance to create a portfolio of low-beta stocks.

Buy These 5 Low-Beta Stocks to Combat a Choppy Market

Top Ranked Value Stocks to Buy for December 3rd

Exantas Capital Corp

Top Ranked Value Stocks to Buy for December 1st

Top Ranked Value Stocks to Buy for November 27th

United Natural Foods

Top Ranked Value Stocks to Buy for November 24th

Northrim BanCorp

Top Ranked Value Stocks to Buy for November 19th

Green Plains Partners

Top Ranked Value Stocks to Buy for November 17th

BURLINGAME, Calif.--(BUSINESS WIRE)--Innoviva, Inc. (NASDAQ: INVA) ("the Company") today reported financial results for the third quarter ended September 30, 2020. Gross royalty revenues of $92.2 million from Glaxo Group Limited (“GSK”) for the third quarter of 2020 included royalties of $63.9 million from global net sales of RELVAR®/BREO® ELLIPTA®, royalties of $11.9 million from global net sales of ANORO® ELLIPTA® and royalties of $16.4 million from global net sales of TRELEGY® ELLIPTA®.1 Dec

Innoviva Reports Third Quarter 2020 Financial Results

Colgate-Palmolive

J.B. Hunt Transport Services

Progressive

Stocks continued yesterday's rally on more stimulus optimism and strong earnings, although Goldman Sachs expressed doubts about the stimulus package. For investors looking to make sense of the markets, our deep learning algorithms have crunched the data to give you a set of Top Buys.

Top Stocks To Buy Today As Markets Rally With Stronger Stimulus Hopes

EPAM Systems

Laureate Education

Perspecta Inc

Despite yesterday’s dip due to poor COVID vaccine and treatment news from Johnson and Johnson and Eli Lilly, the indices are up thus far in October. For investors looking to make sense of these unprecedented times, our deep learning algorithms have crunched the data to give you a set of Top Buys.

Top Stocks To Buy Today As Earnings Continue To Impress Investors

Genmab - ADR

Mersana Therapeutics

Regeneron Pharmaceuticals

Bio-Techne

Vanda Pharmaceuticals

XBiotech

These are the biotech stocks with the best value, fastest growth, and most momentum for Q4 2020.

Top Biotech Stocks for Q4 2020

GlaxoSmithKline

With the approval for the asthma indication, Glaxo's (GSK) Trelegy becomes the first single inhaler triple therapy approved for the maintenance treatment of both asthma and COPD.

Glaxo/Innoviva's Trelegy Ellipta Gets FDA Nod for Asthma

The U.S. Food and Drug Administration (FDA) has approved Innoviva Inc.’s (NASDAQ: INVA) treatment of asthma and for patients with chronic obstructive pulmonary disease (COPD), the company announced, giving shares a boost early Thursday.

Innoviva Wins Another Key FDA Approval for Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) announced the US Food and Drug Administration (FDA) has approved a new indication for Trelegy Ellipta (fluticasone furoate / umeclidinium / vilanterol ‘FF/UMEC/VI’) for the treatment of asthma in patients aged 18 years and older adding to its current license for use in patients with chronic obstructive pulmonary disease (COPD). Trelegy Ellipta is not indicated for relief of acute bronchospasm.

FDA Approves Trelegy Ellipta as the First Once-Daily Single Inhaler Triple Therapy for the Treatment of Both Asthma and COPD in the US

News for Innoviva Stock (INVA)